Size Matters: Novartis Exec Predicts Mid-Sized Firms Will Prevail
This article was originally published in The Pink Sheet Daily
Executive Summary
Large manufacturers who have grown through aggressive merger and acquisition activity will not be able to continue generating double-digit growth under the current big pharma model, Novartis VP Cupit says.